ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone650-210-2900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$42.88 million
Profitability
Miscellaneous
Employees76
Next Earnings Date3/9/2020 (Estimated)
OptionableOptionable
ChemoCentryx (NASDAQ:CCXI) Frequently Asked Questions
What is ChemoCentryx's stock symbol?
ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."
How were ChemoCentryx's earnings last quarter?
ChemoCentryx Inc (NASDAQ:CCXI) released its earnings results on Monday, November, 4th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.06. The biopharmaceutical company earned $10.58 million during the quarter, compared to analysts' expectations of $7.83 million. ChemoCentryx had a negative net margin of 143.30% and a negative return on equity of 88.76%. View ChemoCentryx's Earnings History.
When is ChemoCentryx's next earnings date?
What price target have analysts set for CCXI?
7 brokers have issued 12 month target prices for ChemoCentryx's shares. Their forecasts range from $14.00 to $23.00. On average, they anticipate ChemoCentryx's share price to reach $18.33 in the next year. This suggests a possible upside of 109.0% from the stock's current price. View Analyst Price Targets for ChemoCentryx.
What is the consensus analysts' recommendation for ChemoCentryx?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last year. There are currently 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ChemoCentryx.
What are Wall Street analysts saying about ChemoCentryx stock?
Here are some recent quotes from research analysts about ChemoCentryx stock:
- 1. According to Zacks Investment Research, "ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California. " (11/5/2019)
- 2. HC Wainwright analysts commented, "We base our $23 price target on probability adjusted revenue forecasts for avacopan in AAV and C3G. We use the net present value of our revenue forecast through 2028, apply a 30% probability of success (POS) for avacopan in AAV, a 25% POS for avacopan in C3G, a 3x price/sales multiple, and use our estimated fully diluted year end 2019 net cash of $2.54/share to arrive at our price target. Our P/S multiple of 3x is in-line with ChemoCentryx’s peers that range between 2-5x." (5/7/2019)
Has ChemoCentryx been receiving favorable news coverage?
Media coverage about CCXI stock has been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ChemoCentryx earned a news sentiment score of 1.1 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for ChemoCentryx.
Are investors shorting ChemoCentryx?
ChemoCentryx saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 3,250,000 shares, an increase of 6.2% from the September 30th total of 3,060,000 shares. Based on an average trading volume of 415,100 shares, the short-interest ratio is presently 7.8 days. Currently, 8.0% of the company's stock are short sold. View ChemoCentryx's Current Options Chain.
Who are some of ChemoCentryx's key competitors?
Some companies that are related to ChemoCentryx include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).
What other stocks do shareholders of ChemoCentryx own?
Who are ChemoCentryx's key executives?
ChemoCentryx's management team includes the folowing people:
- Dr. Thomas J. Schall Ph.D., Founder, Pres, CEO & Chairman (Age 60)
- Ms. Susan M. Kanaya, Exec. VP, Chief Financial & Admin. Officer and Sec. (Age 56)
- Dr. Rajinder Singh, Sr. VP of Research (Age 52)
- Dr. Jan L. Hillson M.D., Sr. VP of Drug Devel. (Age 66)
- Dr. Markus J. Cappel, Sr. VP, Chief Bus. Officer & Treasurer (Age 58)
Who are ChemoCentryx's major shareholders?
ChemoCentryx's stock is owned by a number of of retail and institutional investors. Top institutional investors include BB&T Securities LLC (0.23%), Assenagon Asset Management S.A. (0.21%), Alps Advisors Inc. (0.20%), California Public Employees Retirement System (0.08%) and SG Americas Securities LLC (0.04%). Company insiders that own ChemoCentryx stock include Geoffrey M Parker, Markus J Cappel, Plc Glaxosmithkline, Rajinder Singh, Susan M Kanaya and Thomas J Schall. View Institutional Ownership Trends for ChemoCentryx.
Which major investors are selling ChemoCentryx stock?
CCXI stock was sold by a variety of institutional investors in the last quarter, including BB&T Securities LLC and Alps Advisors Inc.. Company insiders that have sold ChemoCentryx company stock in the last year include Geoffrey M Parker, Markus J Cappel, Rajinder Singh, Susan M Kanaya and Thomas J Schall. View Insider Buying and Selling for ChemoCentryx.
Which major investors are buying ChemoCentryx stock?
CCXI stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., California Public Employees Retirement System and SG Americas Securities LLC. View Insider Buying and Selling for ChemoCentryx.
How do I buy shares of ChemoCentryx?
Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is ChemoCentryx's stock price today?
One share of CCXI stock can currently be purchased for approximately $8.77.
How big of a company is ChemoCentryx?
ChemoCentryx has a market capitalization of $509.10 million and generates $42.88 million in revenue each year. The biopharmaceutical company earns $-37,970,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. ChemoCentryx employs 76 workers across the globe.View Additional Information About ChemoCentryx.
What is ChemoCentryx's official website?
How can I contact ChemoCentryx?
ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at 650-210-2900 or via email at [email protected]
MarketBeat Community Rating for ChemoCentryx (NASDAQ CCXI)
MarketBeat's community ratings are surveys of what our community members think about ChemoCentryx and other stocks. Vote "Outperform" if you believe CCXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CCXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
